The Journal of Neuroscience, July 25, 2007, 27(30):7987-8001; doi:10.1523/JNEUROSCI.2180-07.2007
Previous Article | Next Article 
Neurobiology of Disease
Ca2+-Permeable AMPA Receptors Regulate Growth of Human Glioblastoma via Akt Activation
Shogo Ishiuchi,1
Yukari Yoshida,2
Kenichi Sugawara,1
Masanori Aihara,1
Toshiyuki Ohtani,1
Takashi Watanabe,1
Nobuhito Saito,1
Keisuke Tsuzuki,2
Haruo Okado,4
Akiko Miwa,4
Yoichi Nakazato,3 and
Seiji Ozawa2
1Departments of Neurosurgery, 2Neurophysiology, and 3Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan, and 4Department of Molecular Physiology, Tokyo Metropolitan Institute for Neuroscience, Fuchu 183-8526, Japan
Correspondence should be addressed to Dr. Shogo Ishiuchi, Department of Neurosurgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. Email: ishogo{at}showa.gunma-u.ac.jp
Evidence has been accumulated that glioblastoma cells release and exploit glutamate for proliferation and migration by autocrine or paracrine loops through Ca2+-permeable AMPA-type glutamate receptors. Here, we show that Ca2+ signaling mediated by AMPA receptor regulates the growth and motility of glioblastoma cells via activation of Akt. Ca2+ supplied through Ca2+-permeable AMPA receptor phosphorylated Akt at Ser-473, thereby facilitating proliferation and mobility. A dominant-negative form of Akt inhibited cell proliferation and migration accelerated by overexpression of Ca2+-permeable AMPA receptor. In contrast, introduction of a constitutively active form of Akt rescued tumor cells from apoptosis induced by the conversion of Ca2+-permeable AMPA receptor to Ca2+-impermeable receptors by the delivery of GluR2 cDNA. Therefore, Akt functions as downstream effectors for Ca2+-signaling mediated by AMPA receptor in glioblastoma cells. The activation of the glutamate-AMPA receptor-Akt pathway may contribute to the high degree of anaplasia and invasive growth of human glioblastoma. This novel pathway might give an alternative therapeutic target.
Key words: brain tumor; glioblastoma; AMPA receptors; Akt; invasion; calcium signaling
Received Dec. 13, 2006;
revised May 11, 2007;
accepted June 6, 2007.
Correspondence should be addressed to Dr. Shogo Ishiuchi, Department of Neurosurgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. Email: ishogo{at}showa.gunma-u.ac.jp
This article has been cited by other articles:

|
 |

|
 |
 
S. A. Grossman, X. Ye, M. Chamberlain, T. Mikkelsen, T. Batchelor, S. Desideri, S. Piantadosi, J. Fisher, and H. A. Fine
Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
J. Clin. Oncol.,
September 1, 2009;
27(25):
4155 - 4161.
[Abstract]
[Full Text]
[PDF]
|
 |
|